Asthma vs COPD โ Clinical Trial Comparison
Asthma
Reversible airway inflammation and narrowing
VS
COPD
Progressive, irreversible airflow obstruction
Asthma and COPD are the two most common chronic respiratory diseases in the UK, and they can sometimes overlap (Asthma-COPD Overlap, or ACO). However, their trial landscapes are very different. Asthma trials increasingly focus on targeted biologics for severe disease, while COPD trials explore better inhaled combinations, novel anti-inflammatories, and lung regeneration approaches.
Key Differences at a Glance
| Feature | Asthma | COPD |
|---|---|---|
| Primary symptoms | Wheeze, breathlessness, chest tightness, cough (variable) | Chronic cough, sputum, progressive breathlessness (persistent) |
| Common subtypes | Mild persistent, moderate, severe, eosinophilic, allergic, non-allergic | Moderate COPD, severe, very severe, chronic bronchitis, emphysema |
| Severity scoring | ACQ, ACT, FEV1 % predicted | GOLD stage 1โ4, CAT score, mMRC dyspnoea scale |
| Key distinction | Variable, reversible airflow obstruction | Progressive, not fully reversible airflow limitation |
| NICE first-line | SABA + ICS (stepwise approach) | LABA + LAMA (+ ICS if eosinophilic) |
| Prevalence in UK | ~5.4 million (1 in 12) | ~1.2 million diagnosed (est. 2 million total) |
Clinical Trial Availability
| Trial Aspect | Asthma | COPD |
|---|---|---|
| UK trials actively recruiting | 50โ80 studies | 40โ70 studies |
| Most common trial phase | Phase 2โ3 | Phase 2โ3 |
| Top interventions tested | Biologics (anti-IL5, anti-TSLP, anti-IL4R), bronchial thermoplasty, novel inhaled | Triple inhalers, novel anti-inflammatories, biologics (for eosinophilic), pulmonary rehab, stem cells |
| Biologic trials | Major focus area (anti-IL5, anti-IgE, anti-TSLP, anti-IL4R) | Emerging (some eosinophilic COPD trials) |
| Device/delivery trials | Inhaler technology, smart inhalers | Inhaler technology, nebulised therapies, oxygen |
| Digital health trials | Smart inhaler monitoring, app-based asthma plans | Remote monitoring, pulmonary rehab apps |
Exciting Emerging Treatments
Asthma Trials
- Anti-TSLP biologics (tezepelumab) โ targeting upstream airway inflammation
- Anti-IL4Rฮฑ (dupilumab) โ blocking Type 2 inflammation pathway
- Bronchial thermoplasty โ radiofrequency airway smooth muscle reduction
- Once-daily inhaled combinations โ simplifying treatment regimens
- Smart inhaler technology โ adherence monitoring and trigger prediction
- Allergen immunotherapy โ disease-modifying approach for allergic asthma
COPD Trials
- Novel anti-inflammatory agents โ targeting neutrophilic inflammation
- Triple therapy inhalers โ LABA + LAMA + ICS in single device
- Stem cell therapy โ lung tissue regeneration research
- Bronchoscopic lung volume reduction โ for emphysema patients
- Anti-fibrotic agents โ addressing COPD-related lung fibrosis
- Precision medicine โ biomarker-guided treatment selection
๐ก Not sure which trials you qualify for?
Use our Smart Matcher to answer a few questions about your condition and we'll find the most relevant trials for your specific situation โ free, instant results.
Eligibility Differences
Asthma Trial Criteria
- Documented asthma diagnosis with objective testing (spirometry, FeNO, or peak flow variability)
- Asthma Control Questionnaire (ACQ) score thresholds commonly required
- Severe asthma trials: high-dose ICS + additional controller for 12+ months
- Eosinophilic phenotype required for most biologic trials (blood eos โฅ 150โ300)
- Smoking history may exclude (current smokers often excluded from severe asthma trials)
COPD Trial Criteria
- Spirometry confirming post-bronchodilator FEV1/FVC < 0.7
- GOLD stage classification determines which trials are appropriate
- Smoking status tracked (current, former, pack-year history)
- Eosinophil count increasingly used to stratify (eosinophilic vs non-eosinophilic COPD)
- Exacerbation history often required (โฅ2 moderate or โฅ1 hospitalisation in past year)
Frequently Asked Questions
Can I join a clinical trial if I have both Asthma and COPD?
It depends on the specific trial. Many trials allow comorbid conditions as long as the primary condition being studied is clearly dominant. Some trials explicitly exclude patients with significant overlapping conditions. Always check the eligibility criteria carefully and discuss with both the trial team and your specialist.
Which condition has more clinical trials available in the UK?
COPD typically has more actively recruiting trials in the UK. However, both conditions have robust research pipelines with new studies opening regularly.
What should I consider when choosing between trials for these conditions?
Consider which condition impacts your quality of life most, what treatments you've already tried, the trial phase (earlier phases are more experimental), the time commitment involved, and whether the trial offers access to treatments not otherwise available. Your specialist can help you prioritise.